Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 4/20 | 0.59 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MPI | P34949 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 5/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506864 | 0.94 | HSD17B1 (0.56) | HSD17B1HSD17B2CA12CA1CA2 | |
| SCHEMBL16716611 | 0.91 | HSD17B1 (0.51) | HSD17B1HSD17B2CA12CA1CA2 | |
| SCHEMBL21203331 | 0.91 | CYP1A2 (0.52) | HSD17B1HSD17B2CA12CA1CA2 | |
| SCHEMBL17754448 | 0.91 | HSD17B1 (0.51) | HSD17B1HSD17B2CA12CA1CA2 | |
| SCHEMBL31539907 | 0.91 | CYP1A2 (0.52) | HSD17B1HSD17B2CA12CA1CA2 | |
| SCHEMBL21203600 | 0.89 | HSD17B1 (0.50) | HSD17B1HSD17B2CA12CA1CA2 | |
| SCHEMBL21203531 | 0.89 | HSD17B1 (0.50) | HSD17B1HSD17B2CA12CA1CA2 | |
| SCHEMBL8591977 | 0.89 | HSD17B1 (0.50) | HSD17B1HSD17B2CA12CA1CA2 | |
| SCHEMBL12886004 | 0.89 | HSD17B1 (0.50) | HSD17B1HSD17B2CA12CA1CA2 | |
| SCHEMBL29023201 | 0.88 | HSD17B1 (0.51) | HSD17B1HSD17B2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105358541-B | Chiral 4 benzodihydropyrone is formed using chiral pyrrolidine in the presence of phenol or thiophenol | 帝斯曼知识产权资产管理有限公司 | 2017-11-03 | — | — | CN | claimed |
| US-7741240-B2 | Transition metal compounds for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-06-22 | — | — | US | claimed |
| CN-114874153-A | Synthetic method of naphtho [2,1-d ] oxazole compound | 湖南第一师范学院 | 2022-08-09 | — | — | CN | disclosed |
| CN-104684902-B | Epoxide, preparation method, composition epoxy resin and its solidfied material | DIC株式会社 | 2019-05-17 | — | — | CN | disclosed |
| CN-105358541-B | Chiral 4 benzodihydropyrone is formed using chiral pyrrolidine in the presence of phenol or thiophenol | 帝斯曼知识产权资产管理有限公司 | 2017-11-03 | — | — | CN | disclosed |
| CN-102952157-B | Intermediates for the synthesis of benzindene prostaglandins and their preparation | CHIROGATE INTERNATIONAL INC. (CN) | 2016-04-13 | — | — | CN | disclosed |
| CN-105358541-A | Formation of chiral 4-chromanone using chiral pyrrolidine in the presence of phenol or thiophenol | DSM IP ASSETS BV | 2016-02-24 | — | — | CN | disclosed |
| CN-104684902-A | Epoxy compound and method for production thereof, and epoxy resin composition and cured product thereof | DAINIPPON INK & CHEMICALS | 2015-06-03 | — | — | CN | disclosed |
| CN-102952157-A | Intermediates for the synthesis of benzindene prostaglandins and their preparation | CHIROGATE INT INC | 2013-03-06 | — | — | CN | disclosed |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8114997-B2 | N4-acylcytosine nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | GILEAD PHARMASSET LLC | 2007-04-05 | — | — | US | disclosed |
| US-7105527-B2 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2006-09-12 | — | — | US | disclosed |
| EP-1569652-A2 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | Pharmasset Ltd. (BB) | 2005-09-07 | — | — | EP | disclosed |
| US-6908924-B2 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | PHARMASSET, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2004-10-28 | — | — | US | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003063771-A2 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET LTD. (BB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003051306-A2 | N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | ENTPD5, DUT, NT5C3B | HSD17B1 3320/4885HSD17B2 3264/4885CA12 4444/4885 |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | HSD17B1 574/4885HSD17B2 1159/4885CA12 3068/4885 |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | ENTPD5, DUT, PNP | HSD17B1 2671/4885HSD17B2 2864/4885CA12 3389/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | HSD17B1 747/4885HSD17B2 1006/4885CA12 709/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | HSD17B1 3287/4885HSD17B2 3221/4885CA12 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.